Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
November 16, 2022 17:05 ET
|
Vyant Bio, Inc.
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:...
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 16, 2022 16:43 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
November 10, 2022 17:13 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
November 07, 2022 09:00 ET
|
Vyant Bio, Inc.
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
October 27, 2022 17:10 ET
|
Vyant Bio, Inc.
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
August 19, 2022 09:29 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
August 15, 2022 08:05 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
June 01, 2022 18:05 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
May 10, 2022 16:01 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...